Literature DB >> 8640560

Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.

L Mao1, J S Lee, Y H Fan, J Y Ro, J G Batsakis, S Lippman, W Hittelman, W K Hong.   

Abstract

To better understand genetic alterations in oral premalignant lesions, we examined 84 oral leukoplakia samples from 37 patients who had been enrolled in a chemoprevention trial. The samples were analyzed for two microsatellite markers located at chromosomes 9p21 and 3p14. Loss of heterozygosity (LOH) at either or both loci was identified in 19 of the 37 (51%) patients. Of these 19 patients, seven (37%) have developed head and neck squamous cell carcinoma (HNSCC) while only one of 18 (6%) of patients without LOH developed HNSCC. Our data suggest that clonal genetic alterations are common in oral premalignant lesions; that multiple genetic alterations have already occurred in oral premalignant lesions, allowing at least a focal clonal expansion; and that losses of the 9p21 and 3p14 regions may be related to early processes of tumorigenesis in HNSCC. These genetic alterations in premalignant tissues may serve as markers for cancer risk assessment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640560     DOI: 10.1038/nm0696-682

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  99 in total

1.  Molecular analysis of oral lichen planus. A premalignant lesion?

Authors:  L Zhang; C Michelsen; X Cheng; T Zeng; R Priddy; M P Rosin
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa.

Authors:  Keizo Kato; Akira Hara; Toshiya Kuno; Hideki Mori; Tomomi Yamashita; Makoto Toida; Toshiyuki Shibata
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

3.  Smoking and drinking in relation to oral cancer and oral epithelial dysplasia.

Authors:  Douglas E Morse; Walter J Psoter; Deborah Cleveland; Donald Cohen; Mireseyed Mohit-Tabatabai; Diane L Kosis; Ellen Eisenberg
Journal:  Cancer Causes Control       Date:  2007-07-24       Impact factor: 2.506

Review 4.  Tumor Microenvironment in Head and Neck Squamous Cell Carcinomas.

Authors:  Görkem Eskiizmir
Journal:  Turk Arch Otorhinolaryngol       Date:  2015-09-01

5.  An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.

Authors:  Charles M Rudin; Ezra E W Cohen; Vassiliki A Papadimitrakopoulou; Sol Silverman; Wendy Recant; Adel K El-Naggar; Kirsten Stenson; Scott M Lippman; Waun Ki Hong; Everett E Vokes
Journal:  J Clin Oncol       Date:  2003-11-03       Impact factor: 44.544

Review 6.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

7.  Potential use of quantitative tissue phenotype to predict malignant risk for oral premalignant lesions.

Authors:  Martial Guillaud; Lewei Zhang; Catherine Poh; Miriam P Rosin; Calum MacAulay
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  Integrative molecular characterization of head and neck cancer cell model genomes.

Authors:  Ivy F L Tsui; Cathie Garnis
Journal:  Head Neck       Date:  2010-09       Impact factor: 3.147

9.  DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.

Authors:  Pierre Saintigny; Adel K El-Naggar; Vali Papadimitrakopoulou; Hening Ren; You-Hong Fan; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Scott M Lippman; Li Mao
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

10.  New hope for an oral cancer solution: together we can make a difference.

Authors:  Miriam P Rosin; Catherine F Poh; J Mark Elwood; P Michele Williams; Richard Gallagher; Calum MacAulay; Wan W Lam; Ajit Auluck; Lewei Zhang; T Gregory Hislop
Journal:  J Can Dent Assoc       Date:  2008-04       Impact factor: 1.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.